Therapeutic options for different metastatic sites arising from renal cell carcinoma: A review

Author:

Wang Xue1,Qian Lin2,Qian Zengxing1,Wu Qihang3,Cheng Dongying4,Wei Junjun1,Song Lingmin1,Huang Shuaihuai1,Chen Xiaodong1,Wang Ping3,Weng Guobin1ORCID

Affiliation:

1. Zhejiang Key Laboratory of Pathophysiology, Ningbo University, Ningbo, China

2. Department of Urologic Surgery, Ningbo Yinzhou No. 2 Hospital, Ningbo, China

3. Department of Clinical Laboratory, Ningbo Yinzhou No. 2 Hospital, Ningbo, China

4. Department of community, Ningbo Yinzhou No. 3 Hospital, Ningbo, China.

Abstract

Renal cell carcinoma (RCC) stands among the top 10 malignant neoplasms with the highest fatality rates. It exhibits pronounced heterogeneity and robust metastatic behavior. Patients with RCC may present with solitary or multiple metastatic lesions at various anatomical sites, and their prognoses are contingent upon the site of metastasis. When deliberating the optimal therapeutic approach for a patient, thorough evaluation of significant risk factors such as the feasibility of complete resection, the presence of oligometastases, and the patient’s functional and physical condition is imperative. Recognizing the nuanced differences in RCC metastasis to distinct organs proves advantageous in contemplating potential treatment modalities aimed at optimizing survival outcomes. Moreover, discerning the metastatic site holds promise for enhancing risk stratification in individuals with metastatic RCC. This review summarizes the recent data pertaining to the current status of different RCC metastatic sites and elucidates their role in informing clinical management strategies across diverse metastatic locales of RCC.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference147 articles.

1. CHEK2 is a potential prognostic biomarker associated with immune infiltration in clear cell renal cell carcinoma.;Wu;Sci Rep,2023

2. Cancer statistics, 2024.;Siegel;CA Cancer J Clin,2024

3. Delayed metastasis of clear cell renal carcinoma to the colon in the setting of benign kidney disease.;Tagliaferri;Cureus,2022

4. Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment.;Bahadoram;G Ital Nefrol,2022

5. Decrease of phosphorylated proto-oncogene CREB at Ser 133 site inhibits growth and metastatic activity of renal cell cancer.;Wang;Expert Opin Ther Targets,2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3